Cargando…
Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy
Vaccinations are a key prevention measure in fighting the COVID-19 pandemic. The BNT162b2 mRNA vaccine (BioNTech/Pfizer), the first to receive authorization, was widely used in the mass vaccination campaign in Italy. Healthcare workers were identified as a priority group for vaccination, but few stu...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625320/ https://www.ncbi.nlm.nih.gov/pubmed/34835199 http://dx.doi.org/10.3390/vaccines9111269 |
_version_ | 1784606392244502528 |
---|---|
author | Rahmani, Alborz Dini, Guglielmo Orsi, Andrea Sticchi, Laura Bruzzone, Bianca Montecucco, Alfredo Pellegrini, Luca Manca, Alessia Domnich, Alexander Battistini, Angela Kusznir Vitturi, Bruno Zacconi, Sonia Debarbieri, Nicoletta Icardi, Giancarlo Durando, Paolo |
author_facet | Rahmani, Alborz Dini, Guglielmo Orsi, Andrea Sticchi, Laura Bruzzone, Bianca Montecucco, Alfredo Pellegrini, Luca Manca, Alessia Domnich, Alexander Battistini, Angela Kusznir Vitturi, Bruno Zacconi, Sonia Debarbieri, Nicoletta Icardi, Giancarlo Durando, Paolo |
author_sort | Rahmani, Alborz |
collection | PubMed |
description | Vaccinations are a key prevention measure in fighting the COVID-19 pandemic. The BNT162b2 mRNA vaccine (BioNTech/Pfizer), the first to receive authorization, was widely used in the mass vaccination campaign in Italy. Healthcare workers were identified as a priority group for vaccination, but few studies have assessed its reactogenicity among the young working age population. An online survey was conducted to investigate the adverse reactions occurring in the 7 days following the first and second vaccination doses amongst resident doctors of the University of Genoa, employed at the IRCCS Ospedale Policlinico San Martino of Genoa, between 11 January and 16 March 2021. A total of 512 resident physicians were invited to participate in the study (female = 53.2%; mean age = 28.9 years), of whom 296 (female = 53.4%, mean age = 28.9 years) and 275 (female = 55.3%, mean age = 29.1 years) completed the survey after their first and second vaccination doses, respectively. In the 7 days following the first dose, most common adverse reactions were local pain (96.3%), fatigue (42.6%), headache (33.8%), arthromyalgia (28.0%), and 5.1% reported fever, while following the second dose, participants reported local pain (93.5%), fatigue (74.9%), headache (57.5%), arthromyalgia (58.2%), and fever (30.9%), with a higher prevalence among females. Systemic (but not local) reactions increased following the second vaccination, reaching severe intensity in 9.8% of participants and causing three or more events of moderate intensity in 23.7% of participants. Adverse reactions preventing regular daily activities could cause absenteeism among workers. These results can be useful to inform populations of young individuals, set expectations, and improve adherence to vaccination campaigns. |
format | Online Article Text |
id | pubmed-8625320 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86253202021-11-27 Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy Rahmani, Alborz Dini, Guglielmo Orsi, Andrea Sticchi, Laura Bruzzone, Bianca Montecucco, Alfredo Pellegrini, Luca Manca, Alessia Domnich, Alexander Battistini, Angela Kusznir Vitturi, Bruno Zacconi, Sonia Debarbieri, Nicoletta Icardi, Giancarlo Durando, Paolo Vaccines (Basel) Article Vaccinations are a key prevention measure in fighting the COVID-19 pandemic. The BNT162b2 mRNA vaccine (BioNTech/Pfizer), the first to receive authorization, was widely used in the mass vaccination campaign in Italy. Healthcare workers were identified as a priority group for vaccination, but few studies have assessed its reactogenicity among the young working age population. An online survey was conducted to investigate the adverse reactions occurring in the 7 days following the first and second vaccination doses amongst resident doctors of the University of Genoa, employed at the IRCCS Ospedale Policlinico San Martino of Genoa, between 11 January and 16 March 2021. A total of 512 resident physicians were invited to participate in the study (female = 53.2%; mean age = 28.9 years), of whom 296 (female = 53.4%, mean age = 28.9 years) and 275 (female = 55.3%, mean age = 29.1 years) completed the survey after their first and second vaccination doses, respectively. In the 7 days following the first dose, most common adverse reactions were local pain (96.3%), fatigue (42.6%), headache (33.8%), arthromyalgia (28.0%), and 5.1% reported fever, while following the second dose, participants reported local pain (93.5%), fatigue (74.9%), headache (57.5%), arthromyalgia (58.2%), and fever (30.9%), with a higher prevalence among females. Systemic (but not local) reactions increased following the second vaccination, reaching severe intensity in 9.8% of participants and causing three or more events of moderate intensity in 23.7% of participants. Adverse reactions preventing regular daily activities could cause absenteeism among workers. These results can be useful to inform populations of young individuals, set expectations, and improve adherence to vaccination campaigns. MDPI 2021-11-03 /pmc/articles/PMC8625320/ /pubmed/34835199 http://dx.doi.org/10.3390/vaccines9111269 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rahmani, Alborz Dini, Guglielmo Orsi, Andrea Sticchi, Laura Bruzzone, Bianca Montecucco, Alfredo Pellegrini, Luca Manca, Alessia Domnich, Alexander Battistini, Angela Kusznir Vitturi, Bruno Zacconi, Sonia Debarbieri, Nicoletta Icardi, Giancarlo Durando, Paolo Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy |
title | Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy |
title_full | Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy |
title_fullStr | Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy |
title_full_unstemmed | Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy |
title_short | Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy |
title_sort | reactogenicity of bnt162b2 mrna covid-19 vaccine in a young working age population: a survey among medical school residents, within a mass vaccination campaign, in a regional reference teaching hospital in italy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625320/ https://www.ncbi.nlm.nih.gov/pubmed/34835199 http://dx.doi.org/10.3390/vaccines9111269 |
work_keys_str_mv | AT rahmanialborz reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT diniguglielmo reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT orsiandrea reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT sticchilaura reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT bruzzonebianca reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT montecuccoalfredo reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT pellegriniluca reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT mancaalessia reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT domnichalexander reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT battistiniangela reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT kusznirvitturibruno reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT zacconisonia reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT debarbierinicoletta reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT icardigiancarlo reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT durandopaolo reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly |